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Abstract: Severe cutaneous adverse drug reactions (SCARs) represent life-threatening medical
conditions and an appropriate causative diagnosis of these conditions is of the highest importance.
Existing in vivo diagnostic methods are risky or are just contraindicated in these patients. Therefore,
in vitro tests take on greater significance. In this survey, the studies on in vitro assays in SCARs
were identified with a defined searching strategy and strict eligibility criteria. Different methods
in the particular clinical manifestations and the groups of drugs were compared in respect to the
diagnostic parameters obtained. The lymphocyte transformation test and IFNg-ELISpot (Interferon
γ-Enzyme-linked immunospot assay) appeared to have the best evidence currently available. Further
diagnostic assays, which are based mostly on distinct mechanisms of SCARs, may outdo previous
assays but they still need confirmation in a larger group of patients and in more research centers.
Data from pediatric populations and acute generalized exanthematous pustulosis (AGEP) patients
are scarce. Some technical issues, limitations, and modifications of routine laboratory methods are
also discussed.
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1. Introduction
Adverse drug reactions (ADRs) are of significant concern for clinicians and patients. Although
effective and potent drugs are important advances in modern medicine, they are also a major cause
of iatrogenic diseases. Hence, ADRs represent an actual public health problem [1]. The classification
proposed by Rawlins and Thompson may serve as an initial approach to ADRs [2]. They divided
ADRs into type A and type B reactions. Type A reactions, which represent 75–80% of all ADRs,
are dose-dependent, predictable, related to drug pharmacology, and occur in nearly all individuals,
whereas type B reactions, which account for the remaining 20–25% of ADRs, are considered to
be unpredictable, dose-independent, typically unrelated to the pharmacological action of a drug,
and occur only in susceptible patients [3,4]. Type B reactions are also called idiosyncratic drug
reactions [4]. They include immune-mediated drug hypersensitivity reactions (real drug allergies)
and nonallergic hypersensitivity (also called pseudoallergy), which are not immune mediated,
e.g., an alteration in arachidonate metabolism (hypersensitivity to nonsteroidal anti-inflammatory
drugs) or a bradykinin accumulation due to the intake of angiotensin-converting enzyme inhibitors [1].
Immune-mediated drug hypersensitivity reactions (DHRs) are classified into four types (I–IV)
described by Coombs and Gell [5]. The most common are IgE- and T-cell-mediated reactions,
corresponding to type I and type IV, respectively. Type II reactions are based on IgG and IgM
mediated cytotoxic mechanisms. Type III reactions are mediated through an immune complement
complex. Different effector functions of drug-activated T cells led to a subclassification of type IV into
type IVa–IVd [6]. Type IVa and IVb are driven by T-helper 1 cytokines (IFNg, TNFa) and T-helper 2
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cytokines (IL-4, IL-5, IL-13), respectively. Eczemas are typical manifestations of type IVa DHRs, whereas
maculopapular exanthema and drug rash with eosinophilia and systemic symptoms (DRESS) represent
type IVb reactions. Type IVc reactions rely on effector cytotoxic T cells releasing cytokines such as
granzymes, perforin, and granulysins. These cytotoxic mechanisms predominate in drug-induced
bullous skin reactions such as Stevens–Johnson syndrome and toxic epidermal necrolysis but can be
present in other delayed DHRs. Type IVd reactions correspond to IL-8-dependent sterile neutrophilic
inflammation, which is involved in acute generalized exanthematous pustulosis [3].
Coombs and Gell classes, however useful, do not completely cover our current understanding
of the underlying pathophysiology of DHRs. Modifications of nomenclature and classification are
still debated [1,4,7]. The classical explanation for DHRs states that a drug acts as a hapten and binds
covalently to proteins. This process results in the alternation of the protein structure and the generation
of new antigens (hapten–protein complex) [8]. Some drugs are prohaptens and require metabolic
activation (e.g., sulfonamides) to gain the ability to bind irreversibly to protein [1]. Accumulation of
reactive nucleophiles to metabolites may also provide important maturation signals, often referred
to as “danger signals” [9], which play a role in the activation of the innate immune system and in
the development of an effective immune response. A drug and, possibly its reactive metabolite,
can also directly and non-covalently bind to immune receptors such as HLA or TCR proteins [10,11],
then activate T cells and stimulate a specific response (pharmacological interaction with immune
receptor, known as p-i concept) or promote an exchange of peptides embedded in an antigen-binding
site of HLA. The latter process may also induce severe DHRs [12].
Classification of DHRs is also challenging from a clinical point of view because of the huge
variety of clinical presentations and their combinations. Moreover, symptoms of DHRs vary in
respect to chronology and severity. Immediate reactions occur within 1–6 h, typically ≤1 h, after
a culprit drug administration [1,4]. Apart from an anaphylactic shock, they manifest, for instance,
as urticaria, angioedema, rhinitis, bronchospasm, nausea, vomiting, or diarrhea. Nonimmediate
reactions require more time for the symptoms to appear and are either intermediate (5–14 days) or
delayed (2–7 weeks) [13]. The skin as well as the liver and blood cells, are the most commonly affected.
Symptoms range from mild maculopapular or morbilliform exanthemas, through clinical signs
related to organ involvement (e.g., hepatitis, nephritis) and blood dyscrasias (e.g., thrombocytopenia,
eosinophilia), to severe cutaneous adverse drug reactions (SCARs), such as Stevens–Johnson
syndrome/toxic epidermal necrolysis (SJS/TEN), DRESS, and acute generalized exanthematous
pustulosis (AGEP). SCARs represent life-threatening medical conditions and an appropriate causative
diagnosis is of the highest importance, especially for patients receiving several drugs simultaneously.
The complete DHRs workup is based on clinical history and, if possible, on standardized skin
tests, in vitro biological tests, and drug provocation tests. Existing in vivo diagnostic methods have
significant limitations for SCARs. Drug provocation tests, which are considered to be the gold standard
for the identification of the culprit drug, are absolutely contraindicated for severe life-threatening DHRs.
Skin patch tests demonstrate low sensitivity in SJS/TEN [14] and may produce flare up reactions,
especially in DRESS [15]. Moreover, many patients are afraid of re-exposition to suspected drugs.
Therefore, causative diagnosis is based on the estimation of the probability of a causal relationship
between a taken drug and symptoms. Additional diagnostic tests, such as in vitro tests, may bring
this probability closer to the decision threshold (whether or not a patient can take a tested drug in
the future). A number of studies, employing in vitro methods, revealed immunological mechanisms
(mediators and effector cells) involved in the SCARs. Laboratory techniques, such as flow cytomery,
enzyme-linked immunospot (ELISpot), or ELISA, may grasp distinct parameters of a drug-specific T
cells response (e.g., proliferation, surface markers expression, cytokines release) [3] but the translation
of these findings into diagnostic tests is still in progress. There is a gap between the objectives of
researchers and the expectations of clinicians awaiting practical diagnostic tools.
So far, the reviews in this field have been mostly based on experts’ opinions and there are still
many open questions such as the optimal time for testing, the best in vitro read-out system to detect
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drug-induced response, and the dependence of results on particular clinical manifestations of drug
hypersensitivity. We focused on the distinct manifestations of drug hypersensitivity (SJS/TEN, DRESS,
and AGEP) and identified in a systemic way, as described in detail in “Section 4”, the publications
dedicated to in vitro assays in these types of reactions. Next, we compared the diagnostic parameters
of the methods applied in the identified publications. As a specific “diagnostic method”, we considered
a read-out system and a given endpoint together. We also analyzed whether the results of particular
methods depend on the tested drug or group of drugs.
2. Results
2.1. General
Only nine out of 29 studies included in the analysis were dedicated exclusively to SCARs, namely
to DRESS [16–19], SJS/TEN [20,21], or both SJS/TEN and DRESS [22–24]. The other 20 studies were
conducted on patients with different drug hypersensitivity reactions (DHRs). Data concerning SCARs
patients were extracted from these studies.
Altogether, 259 SCARs patients were tested 398 times with different methods. The control groups
consisted of 341 individuals in total. The mean time span between the onset of symptoms and testing
was 4.98 months, with a range from 1 day [23] to 10 years [25]. Children were tested in one study [26],
children and adults in three studies [27–29]. The age of tested individuals was not specified in one
study [16]. The other studies were conducted on adults. In vitro assays were applied as diagnostic
tests in most of the identified articles, however, in a few studies they served strictly as a research tool.
Clinical history served as a main reference for those studied in vitro tests. A clinical drug
causality assessment was carried out using the RegiSCAR criteria [22–24,30], the ALDEN (an algorithm
for drug causality in SJS/TEN) algorithm [20,22,23], classification of Nyfeler and Pichler [27,31],
the Naranjo algorithm [22,32], the Spanish Pharmacovigilance System [18], and the criteria of Karch
and Lasagna [33]. Otherwise, it was based on a suggestive history, a typical clinical picture, and an
exclusion of alternative causes.
2.2. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)
A total of 138 DRESS patients were investigated in 20 out of 29 of the analyzed studies (Table 1).
The in vitro methods (presented as “specific response marker/technique”) most often applied to
detect culprit drugs were: peripheral blood mononuclear cells (PBMC) proliferation/lymphocyte
transformation tests (LTT), IFNg releasing cells/ELISpot assay, IL-4 releasing cells/ELISpot,
and granulysin concentration in cell culture supernatant/ELISA. Sensitivities and specificities achieved
with these methods are shown in Table 2. The drugs most often tested were aromatic antiepileptics
(in 29 patients) and allopurinol/oxpurinol (in 28 patients) (Table 1). The results for particular drugs
and their corresponding methods are shown in Table 3.
2.3. Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)
A total of 115 SJS patients were investigated in 16 out of 29 of the analyzed studies (Table 4).
The in vitro methods (presented as “specific response marker/technique”) most often applied to
detect culprit drugs were: PBMC proliferation/LTT, IFNg releasing cells/ELISpot, IL-4 releasing
cells/ELISpot and granulysin concentration in cell culture supernatant/ELISA, granulysin (Grl) in
CD3+CD4+/flow cytometry, granzyme B (GrB) releasing cells/ELISpot, and INFg concentration
in cell culture supernatant/cytokine beads array. The sensitivities and specificities achieved with
these methods are shown in Table 5. The drugs most often tested were aromatic antiepileptics
(in 25 patients) and allopurinol/oxpurinol (in 20 patients) (Table 4). The results for particular drugs
and their corresponding methods are shown in Table 6.
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Table 1. Studies in which drug rash with eosinophilia and systemic symptoms (DRESS) patients were investigated.
Study Endpoint (Activation Marker) Read-Out System (Technique) Drug
Patients Controls
N Performed Tests Positive Tests N/Positive Tests
Karami, 2016 proliferation LTT aAEDs 9 9 5 24/1
Ye, 2016 proliferation LTT isoniazid 4 4 4 not reported
Cabanas, 2014 proliferation LTT piperacillin 8 8 8 not reported
Valeyrie-Allanore, 2014 proliferation LTT ND 12 12 4 20/0
Yun, 2013 proliferation LTT ALP/OXP (1) 7 7 7 7/NA (2)
Hanafusa, 2012 proliferation LTT aAEDs 3 3 2 not reported
Kano, 2007 proliferation LTT
aAEDs 4 4 3
4/0
mexiletine 1 1 1
Kanny, 2005 proliferation LTT ICM 2 2 1 10/0
Naisbitt, 2003 proliferation LTT aAEDs 1 1 1 not reported
Ikeda, 1998 proliferation BrdU FITC Various (3) 18 18 13 27/0
Houwerzijl, 1979 proliferation LTT aAEDs 7 7 7 10/0
Warrinoton, 1979 proliferation LTT isoniazid 8 8 6 19/0
Kato, 2016
proliferation LTT
SMX/TRM 1
1 1 3/0 (4)
IFNg ELISpot 1 1 3/0 (4)
proliferation LTT
ALP/OXP 1
1 0
IFNg ELISpot 1 0
proliferation LTT
aAEDs 3
3 2
IFNg ELISpot 3 0
Haw, 2016
proliferation LTT
ND
5
5 2
not reportedIFNg ELISpot 5 2
IL-4 ELISpot 5 5
Polak, 2013
proliferation LTT
ND
7
7 1 14/1 (5)
IFNg ELISpot 7 5 14/1 (5)
IL-4 ELISpot 5 4 14/2 (5)
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Table 1. Cont.
Study Endpoint (Activation Marker) Read-Out System (Technique) Drug
Patients Controls
N Performed Tests Positive Tests N/Positive Tests
Sachs, 2002
proliferation LTT
aAEDs
2
2 2 15/0
IFNg ELISA 1 1 5/3
IL-5 ELISA 2 2 15/0
IL-10 ELISA 2 2 5/0
Chung, 2015
proliferation LTT
ALP/OXP (1)
3 3 1 not reported
Grl ELISA 7 7 6 34/3
Klaewsongkram, 2016 IFNg ELISpot ALP/OXP 13 13 9 21/1
Esser, 2012 IFNg ELISpot abacavir (6) 12 12 5 17/0
Halevy, 2005 INFg ELISA various 3 3 2 22/not reported
(1) only OXP induced positive response; (2) Controls not tested with LTT; (3) ceflazidim, ciprofloxacin, erythromycin, ethambutol, isoniazid, nifedipine, nilvadipine, ofloxacin, piperacillin,
propafenone, propylthiouracil, pyrazinamide, rifampicin, ticlopidine; (4) It refers to the corresponding endpoint and read-out system; (5) Number of positive tests estimated from specificity
given by authors, (6) Only HLA*57:01 negative individuals were analyzed. Abbreviations: N, number of the tested individuals (patients/ controls); aAEDs, aromatic antiepileptic drugs
(phenobarbital, phenytoin, carbamazepine, lamotrigine); ALP/OXP, allopurinol/oxpurinol; BrdU FITC, bromodeoxyuridine fluorescein isothiocyanate assay; ELISA, enzyme-linked
immunosorbent assay; ELISpot, enzyme-linked immunospot assay; Grl, granulysin; ICM, iodinated contrast media (ioxaglate, iohexol); LTT, lymphocyte transformation test; NA, not
applicable; ND, not determined; SMX/TRM, sulfamethoxazole/trimethoprim.
Table 2. Sensitivity and specificity of different methods (wherever >5 DRESS patients were tested).
Method
Patients Controls
Sensitivity Specificity
Performed Tests Positive Tests Performed Tests Positive Tests
proliferation LTT/BrdU FITC 106 71 146 2 0.67 0.99
IFNg ELISpot 42 22 55 2 0.52 0.96
IL-4 ELISpot 10 9 14 2 0.90 (1) 0.86 (1)
Grl ELISA 7 6 34 3 0.86 (2) 0.91 (2)
(1) based on data from a single center, (2) based on data from tests with a single drug (ALP/OXP), abbreviations: as in Table 1.
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Table 3. Sensitivities corresponding with particular drugs (wherever >5 DRESS patients were tested with the same method).
Drug Method
Patients
Sensitivity
Performed Tests Positive Tests
aAEDs proliferation LTT 29 22 0.76
Abacavir IFNg ELISpot 12 5 0.42 (1)
ALP/OXP
proliferation LTT 11 8 0.73
IFNg ELISpot 14 9 0.64
Grl ELISA 7 6 0.86
isoniazid proliferation LTT 12 10 0.83
piperacillin proliferation LTT 8 8 1.00 (1)
(1) based on data from a single study, abbreviations: as in Table 1. Data for specificity not available (results for particular drugs not reported in control groups in most studies).
Table 4. Studies in which Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) patients were investigated.
Study Endpoint (Activation Marker) Read-Out System (Technique) Drug
Patients Controls
N Performed Tests Positive Tests N/Positive Tests
Karami, 2016 proliferation LTT aAEDs 11 11 7 24/1
Srinoulprasert, 2014
proliferation LTT sulfamethoxazole 1 1 0
3/0proliferation LTT aAEDs 1 1 1
proliferation LTT mefenamic acid 1 1 0
Valeyrie-Allanore, 2014 proliferation LTT ND 22 22 7 20/0
Kano, 2007 proliferation LTT
minocycline 1 1 0
4/0paracetamol 1 1 0
Naisbitt, 2003 proliferation LTT aAEDs 2 2 1 not reported
Hari, 2001 proliferation LTT β-lactams 3 3 3 95/1
Roujeau, 1985 proliferation LTT Various (1) 12 12 0 not reported
Kato, 2016
proliferation LTT
celecoxib 1
1 0 3/0 (2)
IFNg ELISpot 1 0 3/0 (2)
proliferation LTT
ALP/OXP 1
1 0
IFNg ELISpot 1 0
proliferation LTT
aAEDs 1
1 0
IFNg ELISpot 1 0
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Table 4. Cont.
Study Endpoint (Activation Marker) Read-Out System (Technique) Drug
Patients Controls
N Performed Tests Positive Tests N/Positive Tests
Rozieres, 2009
proliferation LTT
amoxicillin 1
1 1 11/0
IFNg ELISpot 1 1 11/0
Haw, 2016
proliferation LTT
ND 4
4 2
not reportedIFNg ELISpot 4 4
IL-4 ELISpot 4 1
Polak, 2013
proliferation LTT
ND 9
9 5 14/1 (3)
IFNg ELISpot 9 7 14/1 (3)
IL-4 ELISpot 8 4 14/2 (3)
Klaewsongkram, 2016 IFNg ELISpot ALP/OXP 11 11 8 21/1
Halevy, 2008 IFNg ELISA paracetamol 1 1 1 11/4 (3)
Chung, 2015 proliferation LTT ALP/OXP (4)
2 2 1 not reported
Grl ELISA 7 7 6 34/3
Porebski, 2013 (5)
proliferation LTT
aAEDs 9
9 2 18/0 (2)
Grl (6) FACS 9 5 18/0 (2)
GrB ELISpot 9 3 18/1 (2) (3)
IFNg CBA 7 4 18/1 (2) (3)
proliferation LTT
sulphonamides 4
4 1
Grl (6) FACS 4 1
GrB ELISpot 4 1
IFNg CBA 2 1
proliferation LTT
ALP/OXP 1
1 0
Grl (6) FACS 1 1
GrB ELISpot 1 1
IFNg CBA 1 1
proliferation LTT
mefenamic acid 1
1 1
Grl (6) FACS 1 1
GrB ELISpot 1 0
IFNg CBA 1 0
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Table 4. Cont.
Study Endpoint (Activation Marker) Read-Out System (Technique) Drug
Patients Controls
N Performed Tests Positive Tests N/Positive Tests
Martin, 2010
IL-5 (7)
FACS aAEDs 1
1 1 10/0 (2)
IFNg (7) 1 0 10/0 (2)
IL-10 (7) 1 0 10/0 (2)
IL-5 (7)
FACS amoxicillin 1
1 1
IFNg (7) 1 1
IL-10 (7) 1 1
IL-5 (7)
FACS proguanil 1
1 1
IFNg (7) 1 1
IL-10 (7) 1 1
(1) oxyphenbutazone, cotrimoxazole, piroxicam, carbamazepine, fenbufen, flurbiprofen, noramidopyrine, sulfadiazine; (2) It refers to the corresponding endpoint and read-out system;
(3) Number of positive tests estimated from specificity given by authors; (4) only OXP induced positive response; (5) only selected methods are shown; (6) in CD3+CD4+; (7) in CD3+CD4+
and CD3+CD8+. Abbreviations: N, number of the tested individuals (patients/ controls); aAEDs, aromatic antiepileptic drug (phenobarbital, phenytoin, carbamazepine, lamotrigine);
ALP/OXP, allopurinol/oxpurinol; CBA, cytokine beads array; ELISA, enzyme-linked immunosorbent assay; ELISpot, enzyme-linked immunospot assay; FACS, fluorescence-activated cell
sorting, applied in flow cytometry; GrB, granzyme B; Grl, granulysin; LTT, lymphocyte transformation test; ND, not determined.
Table 5. Sensitivity and specificity of different methods (wherever >5 SJS/TEN patients were tested).
Method
Patients Controls
Sensitivity Specificity
Performed Tests Positive Tests Performed Tests Positive Tests
proliferation LTT 95 35 192 3 0.37 0.98
IFNg ELISpot 28 20 49 2 0.71 0.96
IL-4 ELISpot 12 5 14 2 0.42 0.86
Grl ELISA 7 6 34 3 0.86(1) 0.91 (1)
Grl in CD3+CD4+ FACS 15 8 18 0 0.53 1.00
GrB ELISpot 15 5 18 1 0.33 0.94
IFNg CBA 11 6 18 1 0.55 0.94
(1) based on data from tests with a single drug (ALP/OXP), abbreviations: as in Table 1.
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Table 6. Sensitivities corresponding with particular drugs (wherever ≥5 SJS/TEN patients were tested with the same method).
Drug Method
Patients
Sensitivity
Performed Tests Performed Tests
aAEDs proliferation LTT 29 14 0.48
aAEDs (1)
Grl in CD3+CD4+ FACS 9 5 0.56
GrB ELISpot 9 3 0.33
IFNg CBA 7 4 0.57
ALP/OXP
proliferation LTT 5 1 0.20
IFNg ELISpot 12 8 0.67
ALP/OXP (1) Grl ELISA 7 6 0.86
Sulphonamides proliferation LTT 5 1 0.20
(1) based on data from a single study, abbreviations: as in Table 1. Data for specificity not available (Results for particular drugs not reported in control groups in most studies).
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2.4. Acute Generalized Exanthematous Pustulosis (AGEP)
Six AGEP patients were investigated in three out of 29 analyzed studies (Table 7). Results for
in vitro methods applied in these studies as well as the tested drugs are shown in Table 7.
Table 7. Studies in which acute generalized exanthematous pustulosis (AGEP) patients were investigated.
Study
Endpoint
(Activation
Marker)
Read-Out
System
(Technique)
Drug
Patients Controls
N PerformedTests
Positive
Tests
N/Positive
Tests
Srinoulprasert,
2014 proliferation LTT amoxicillin 2 2 2 3/0
Gaspard, 2000 IFNg mRNA RT-PCR amoxicillin
2 2 2 11/4
IL-4 mRNA RT-PCR 2 0 11/0
Schmid, 2006 proliferation LTT ciprofloxacin 2 2 2 notreported
Abbreviations: lymphocyte transformation test (LTT); reverse transcription polymerase chain reaction (RT-PCR).
2.5. Modifications
Some modifications of routine methods were evaluated in a few studies. IFNg ELISpot, which was
performed using PBMCs stimulated with anti-cluster of differentiation (CD)-3/CD28 antibody-coated
microbeads and IL-2 for seven days before exposure to the culprit drugs, was far more sensitive than
the conventional drug-induced IFNg ELISpot or LTT [32]. Removal of Treg/CD25hi cells, which have
a suppressive effect on drug-induced proliferation, increased LTT sensitivity without affecting its
specificity [34]. The presence anti-programmed death ligand 1 antibody (anti-PD-L1) during PBMC
incubation increased sensitivity of IFNg-ELISpot assay in DRESS patients [23]. The combined addition
of anti-CTLA4 and anti-PDL1 antibodies to PBMC cultures increased drug-induced proliferation in
SJS/TEN and DRESS patients [24]. After the pre-incubation of PBMCs from SJS/TEN patients with
IL-7/IL-15, the enhancement of the drug-specific response, measured by granzyme B and granulysin
release, was inconsistent [20].
2.6. Additional Studies
Six studies, which provide valuable data, were not included to the analysis because they did not
fulfill eligibility criteria. PBMCs, which were sampled from SCARs patients, released after stimulation
with culprit drugs, a panel of Th1 and Th2 cytokines (IL-2, IFNg, IL-4, IL-5, and IL-13) detectable
with ELISpot assay [35]. In SJS/TEN patients, the sFasL levels were specifically increased in the
supernatant of PBMCs cultured with culprit drugs [36]. Drug-specific T cells from patients with AGEP
produce significantly more IL-8 in comparison to drug-specific T cells from patients with other types of
drug-induced exanthemas [37]. Measurement with ELISpot assay of drug-specific granzyme B release
by PBMC from SJS/TEN and DRESS patients allowed authors to identify the offending agents [38].
LTT-positive patients with SJS/TEN, DRESS, and AGEP showed a significant CD69 up-regulation
on T cells after 48 h of stimulation with the culprit drugs [39]. Among the 17 cytokines/chemokines
analyzed, IL-2, IL-13, and IFNg secretion in response to sulphonamides was significantly increased in
DRESS and SJS/TEN patients [40].
3. Discussion
3.1. General Considerations
The number of studies exclusively dedicated to a practical approach to in vitro diagnosis of SCARs
that also fulfill obvious and relatively simple eligibility criteria is low. However, by extracting data
from other studies on different DHR including SCARs, we could collect results of different diagnostic
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laboratory methods from over 250 SCARs patients and from even more control individuals. The mean
time span between the onset of SCARs symptoms and testing (about 5 months) was reasonable,
however, it remained within a wide range. We did not analyze this issue in detail because, in our
opinion, there was not enough data to draw a conclusion regarding the optimal timing for testing after
SCARs. The pediatric population is to a very small extent represented in the analyzed studies.
3.2. Assays in Particular Severe Cutaneous Adverse Drug Reactions (SCARs)
LTT has been used for detecting culprit drugs in drug hypersensitivity reactions since the
1970s [41]. Also, nowadays, this is the most often used test in DHRs, as our findings have
shown (Tables 1 and 4). LTT also served as a reference assay in studies evaluating the other
methods [35,36,38–40]. In the studies that we identified, LTT showed a high specificity (98–99%),
whereas sensitivity was considerably low for SJS/TEN patients (37%) (Table 5) but higher for DRESS
patients (67%) (Table 2). Regarding the sensitivities of the particular groups of tested drugs, we did
not find substantial differences between DRESS patients (sensitivities were within the range 73–83%
and in the one study with piperacillin—100%) (Table 3). In SJS/TEN patients, we found the values of
sensitivities from 20% (allopurinol/oxpurinol and sulphonamides) up to 48% (aromatic antiepileptic
drugs) (Table 6).
The second most often used test identified with our search strategy was IFNg-ELISpot. In comparison
to LTT, it was found to have a similar sensitivity and specificity in DRESS, but a, clearly, higher
sensitivity (71%) in SJS/TEN (Tables 2 and 5). Regarding the sensitivities in the particular
groups of tested drugs, IFNg-ELISpot appeared to have sensitivities from 42% (abacavir) to 64%
(allopurinol/oxpurinol) in DRESS, and up to 67% (allopurinol/oxpurinol) in SJS/TEN (Tables 3 and 6).
The other methods applied for the detection of a culprit drug in SJS/TEN or DRESS were
investigated in a very limited number of studies. These methods primarily follow distinct effector
mechanisms of SJS/TEN or DRESS (for instance granulysin or granzyme B release) and seem promising.
However, it is difficult to draw convincing conclusions from their results because they were conducted
with a single drug only (Grl-ELISA, sensitivity 86% in SJS/TEN) [22] or in a single center (Grl in
CD3+CD4+, sensitivity 56% in SJS/TEN; IL-4-ELISpot, sensitivity 90% in DRESS) [20,26,42] and, until
now, an overall number of tested individuals has generally been small.
There are more different in vitro methods, which have been investigated in SJS/TEN (Table 4)
rather than in DRESS (Table 1) because SJS/TEN is more demanding in respect to a causal diagnosis.
Data on in vitro diagnoses of AGEP are very limited (Table 7) but LTT seems to be efficient in this
indication. Some valuable studies have been missed, for instance because data for a particular type
of clinical manifestation (DRESS, SJS/TEN, AGEP) could not be extracted from pooled results [43].
Patch tests, which can improve the in vitro test results, seem to be of value for DRESS and AGEP,
with sensitivities of 64% and 58%, respectively [14]. In the same study, the sensitivity of patch tests in
SJS/TEN patients was only 24% [14]. However, it can reach up to 62.5% in some selected populations
(e.g., carbamazepine-induced SJS/TEN HLA-B*1502+ patients) [44].
3.3. Technical Issues and Limitations
In opposition to laboratory tests for immediate DHR (specific IgE, basophil activation test),
in vitro diagnostic assays in delayed DHRs, including SCARs, take more time due to a long-lasting cell
culture. Their protocols consist of more steps, which require handling instead of automated procedures.
This can obviously result in a higher variability of results. Also, minor differences in experimental
settings between laboratories, such as incubation time or sample storage conditions, may be a source of
additional variability. Furthermore, different authors apply different methods to calculate the cut-off
values in different assays, e.g., the stimulation index (cut-offs from 1.8 up to 4) [45,46], the mean
of all the background samples plus two standard deviations [26,42], the mean of relative increase
in control subjects plus 2–3 standard deviations [33,47], and receiver operator characteristic (ROC)
curves [20,23,31]. Cut-off levels often rely on an average response to different drugs, which are tested
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together in the controls. However, a response may differ depending on a drug, e.g., radio-contrast
media or β-lactams in LTT [3]. Thereby, the application of drug-specific thresholds in in vitro tests for
DHR would be an optimal, albeit relatively rarely used, approach. To sum up, in the case of in vitro
diagnostic assays for SCARs, the normal range in every single laboratory has to be well established
and inter-laboratory comparisons should take into account the issues listed above.
Another concern relating to our results is the primary drug causality assessment, which is used as
reference for investigated diagnostic laboratory tests. Different methods were applied in the identified
studies from typical clinical history to very precise tools, such as the ALDEN algorithm. They are
listed in the Section 2. Actually, they differ from one another in respect to probability of drug causality,
which affects the results. If some patients with DHR tested with in vitro assays are not true positive
cases, the obtained sensitivity is obviously biased downwards. Also, if two or more assays are
performed in different patient groups with diverse percentages of true positive cases, the comparison
between the assays is influenced by these differences.
3.4. Unmet Needs to Be Shown by the Study and Outlook for the Future
Undoubtedly, more studies have to be conducted. They should address the most promising
methods and involve well-defined clinical entities (in respect to culprit drugs and clinical
manifestations, e.g., allopurinol induced DRESS) and patients with a high probability of a causal
relationship between the suspected drug and SCARs symptoms, especially patients from seldom
investigated groups such as the pediatric population and AGEP cases.
Another challenge is managing potential external sources of variability (time span between
symptoms and testing, time and conditions of samples storage, influence of drugs taken by patients on
results), as well as internal sources of laboratory variability.
In view of the fact that investigated assays demonstrate low sensitivities in some patients,
combining assays, which measure drug-specific responses in different end-points (e.g., granulysin,
IFNg, granzyme B) may increase the overall sensitivity [20]. It seems to be a promising strategy in the
most difficult cases, as long as it does not affect the specificity of the identification of the culprit drug.
Diagnostic laboratory methods in delayed DHR, especially SCARs, demand acquaintance with
this field and practice and, therefore, at present, and most probably in the future, these methods are
only performed in a limited number of specialized centers. However, an, at least partial, automation
of laboratory techniques may contribute to the development of some in vitro methods, serving as
a screening step in diagnostic process.
4. Methods
A comprehensive search of available English-language literature was carried out on PubMed.
The search focused on studies describing or potentially describing diagnostic in vitro methods in
severe cutaneous adverse drug reactions. The entry terms used were “in vitro”, “laboratory diagnosis”,
“drug allergy”, “drug hypersensitivity”, “Stevens–Johnson Syndrome”, “SJS”, “Toxic Epidermal
Necrolysis”, “Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome”,” DRESS”, “Acute
Generalized Exanthematous Pustulosis”, and “AGEP” and were combined using Boolean operators.
The search strategy consisted of: set 1, “in vitro”, set 2, laboratory diagnosis; set 3, (“drug allergy” or
“drug hypersensitivity” or “Stevens–Johnson Syndrome” or “Toxic Epidermal Necrolysis” or “SJS”
or “Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome” or “DRESS” or “Acute
Generalized Exanthematous Pustulosis” or “AGEP”); and set 4, set 1 AND set 2 AND set 3. Searches
were last updated on 7 April 2017. A total of 554 items were identified and assessed on the basis
of their title and abstract or in full if no abstract was available. Forty-one were included in further
analysis. An additional 29 references were identified from the bibliographies of the retrieved articles.
In total, 29 articles from both groups met the eligibility criteria and were reviewed and evaluated in
detail (Figure 1) [16–34,42,45–53].
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A limitation that needs to be noted is the evaluation of the identified items by a single reviewer,
however, the eligibility criteria adopted for a study inclusion were reasonably objective and evident.
The studies considered for inclusion were conducted with the participation of patients with SCARs,
who had clearly stated a diagnosis of SJS/TEN, DRESS, or AGEP (or whether a definite diagnosis
could be drawn on the basis of the clinical data provided in an article) and underwent the unbiased
selection to the study (i.e., consecutive individuals). We excluded case reports (due to possible bias for
cases in favor of patients with positive results to diagnostic tests), studies with preselected patients
(i.e., only individuals with positive LTT) and studies without the defined criteria for determining
laboratory tests as positive or negative.
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5. Conclusions
Patients, as ell as many physicians, often expect a definitive answer to what is a causative drug
in SCARs from in vitro tests. Such a clear-cut answer is only possible in some patients when the result
of the test is clearly positive, which is limited by the sensitivity of the assay. Nevertheless, in vitro
diagnostic tests possess a decisive influence on the management of a substantial part of SCARs patients.
At the moment, LTT is undoubtedly the best proven diagnostic assay in the clinical practice
of SCARs. The next one: IFNg-ELISpot, is also quite well established. Further diagnostic assays,
which are based mostly on distinct mechanisms of SCARs, may outdo the previous ones but they
still need confirmation in larger groups of patients and in more research centers. To efficiently collect
new evidence on the diagnostic accuracy of upcoming diagnostic assays, the studies should focus on
well-defined patient groups. Data from pediatric populations and AGEP patients are scarce, which
reflects difficulties in patients’ enrolment. Information about these groups is extrapolated from the
adults and other SCARs, respectively.
Conflicts of Interest: The author declares no conflict of interest.
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Abbreviations
ADRs Adverse drug reactions
aAEDs Aromatic antiepileptic drugs
AGEP Acute Generalized Exanthematous Pustulosis
ALDEN Algorithm of drug causality for epidermal necrolysis
ALP Allopurinol
BrdU FITC Bromodeoxyuridine fluorescein isothiocyanate assay
CBA Cytokine beads array
CD Cluster of differentiation
CTLA4 Cytotoxic T-lymphocyte-associated protein 4
DHRs Drug hypersensitivity reactions
DRESS
Drug Rash with Eosinophilia and Systemic
Symptoms
ELISA Enzyme-linked immunosorbent assay
ELISpot Enzyme-linked immunospot assay
FACS Fluorescence-activated cell sorting
GrB Granzyme B
Grl Granulysin
HLA Human Leukocyte Antigens
ICM Iodinated contrast media
IFNg Interferon γ
IL Interleukin
LTT Lymphocyte transformation test
NA Not applicable
ND Not determined
OXP Oxpurinol
PBMC Peripheral blood mononuclear cells
PD-L1 Programmed cell death-ligand 1
RegiSCAR Registry of severe cutaneous adverse drug reactions
ROC Receiver operator characteristic curve
RT-PCR Reverse transcription polymerase chain reaction
SCARs Severe cutaneous adverse drug reactions
sFasL Soluble factor-related apoptosis ligand
SJS Stevens–Johnson Syndrome
SMX Sulfamethoxazole
TCR T-cell receptor
TEN Toxic Epidermal Necrolysis
TNFa Tumor necrosis factor α
TRM Trimethoprim
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